Goldman Sachs Group Inc. Has $1.33 Million Stock Position in Dianthus Therapeutics, Inc. $DNTH

Key Points

• Goldman Sachs Group Inc. reduced its stake in Dianthus Therapeutics, Inc. by 64.7%, owning 73,430 shares worth approximately $1.33 million after selling 134,637 shares in the first quarter.
• Other institutional investors, such as Octagon Capital Advisors and Vestal Point Capital, increased their holdings in Dianthus, with Vestal Point raising its stake by 58.1% to over 1.7 million shares.
• Dianthus reported a loss of ($0.88) earnings per share for the last quarter, missing analysts' expectations, and its current average rating among analysts is "Buy" with a target price of $61.57.

Goldman Sachs Group Inc. trimmed its position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 64.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 73,430 shares of the company's stock after selling 134,637 shares during the quarter. Goldman Sachs Group Inc. owned 0.23% of Dianthus Therapeutics worth $1,332,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of DNTH. US Bancorp DE boosted its holdings in Dianthus Therapeutics by 2,013.3% in the first quarter. US Bancorp DE now owns 1,585 shares of the company's stock valued at $29,000 after purchasing an additional 1,510 shares during the period. BNP Paribas Financial Markets acquired a new position in Dianthus Therapeutics in the fourth quarter worth approximately $59,000. GAMMA Investing LLC lifted its position in Dianthus Therapeutics by 3,030.6% during the 1st quarter. GAMMA Investing LLC now owns 3,882 shares of the company's stock worth $70,000 after acquiring an additional 3,758 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Dianthus Therapeutics by 4.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company's stock valued at $280,000 after acquiring an additional 618 shares during the period. Finally, Invesco Ltd. lifted its holdings in Dianthus Therapeutics by 38.7% in the first quarter. Invesco Ltd. now owns 15,978 shares of the company's stock valued at $290,000 after buying an additional 4,457 shares during the period. Hedge funds and other institutional investors own 47.53% of the company's stock.

Dianthus Therapeutics Stock Down 5.5%

DNTH traded down $2.12 during midday trading on Friday, hitting $36.75. The company had a trading volume of 1,569,681 shares, compared to its average volume of 1,047,515. The stock's 50 day moving average price is $24.83 and its 200 day moving average price is $21.10. The company has a market capitalization of $1.18 billion, a price-to-earnings ratio of -11.31 and a beta of 1.46. Dianthus Therapeutics, Inc. has a 52 week low of $13.36 and a 52 week high of $39.87.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.02). Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 34.72%. The business had revenue of $0.19 million for the quarter, compared to analysts' expectations of $0.87 million. Research analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Robert W. Baird lifted their price objective on shares of Dianthus Therapeutics from $50.00 to $67.00 and gave the stock an "outperform" rating in a research note on Tuesday, September 9th. HC Wainwright restated a "buy" rating and set a $40.00 target price on shares of Dianthus Therapeutics in a report on Monday, September 8th. Guggenheim upped their price target on Dianthus Therapeutics from $92.00 to $100.00 and gave the stock a "buy" rating in a research note on Tuesday, September 9th. William Blair initiated coverage on Dianthus Therapeutics in a report on Wednesday, July 2nd. They issued an "outperform" rating for the company. Finally, Wedbush boosted their price target on Dianthus Therapeutics from $42.00 to $44.00 and gave the stock an "outperform" rating in a research report on Friday, September 12th. Nine equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $61.57.

Insider Activity at Dianthus Therapeutics

In related news, CFO Ryan Savitz sold 20,000 shares of Dianthus Therapeutics stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $35.00, for a total value of $700,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 16.56% of the stock is owned by insiders.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.